Assertio Holdings, Inc. (NASDAQ:ASRT) Q1 2024 Earnings Call Transcript

Page 2 of 2

Thomas Flaten: Got it. Appreciate it. Thanks everyone.

Heather Mason: Thank you.

Operator: As there are no further questions in the queue at this time, this concludes our Q&A session. I would like to turn the call over back to Heather Mason for closing remarks.

Heather Mason: Thank you, and I appreciate everyone who’s joined us today. And I hope that today’s call has given clarity that we are doing what we said we were going to do. Our intent is to grow Rolvedon, manage Indocin, ensure rightsized operating expenses, maintain cash generation, be active on the business development front, close in on a CEO candidate. And as we keep moving forward, we will apprise you of any additional developments. If you’d like to arrange a call with management, please contact Matt Kreps directly, and we will be happy to schedule a time. Once again, thank you for joining.

Operator: Ladies and gentlemen, this concludes today’s conference call. Thank you for your participation. You may now disconnect.

Follow Assertio Therapeutics Inc (NASDAQ:ASRT)

Page 2 of 2